Drug Trial Radar · NCT05624229
Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding
Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
672
Planned (sponsor's estimate)
Start
Oct 1, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- West China HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute Variceal Bleeding (AVB) in patients with liver cirrhosis is a common clinical critical disease. There is little evidence for the effect of proton pump inhibitor (PPI) use in patients with AVB, and there is no study on the efficacy of PPI combined with standard therapy in patients with AVB.
Conditions
- Upper Gastrointestinal Hemorrhage
Interventions
Proton Pump InhibitorsDrug
PPI infusion continued to use for 5 days in experimental group
No Proton Pump InhibitorsDrug
PPI infusion stopped in standard group after endoscopy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-day treatment failure rateTime frame: 5 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.